肺癌具有很高的死亡率和和很低的治癒率，其中最重要的是轉移率非常的高，而放射治療和化學治療都會產生許多的副作用，目前常用於治療肺癌的標靶治療，後期也會產生強烈的抗藥性，因此，我們希望可以找到新的治療，而許多文獻顯示天然藥物可以用來治療癌症，除了毒性較低也會有較低的副作用。經過藥物的篩選找到了中藥BP010W可以抑制肺癌細胞的爬行能力，因此本文選擇BP010W做更深入的研究。我們將BP010W藥物分層，依據乙醇濃度變化量0%、20%、50%和95%，依序得到不同的成分，並發現BP010W 20%和BP010W 50%的分離物有更好的抑制效果。我們也透過利用生物資訊的方法和文獻的參考探討雌激素途徑會影響肺癌的調控，因此我們篩選出中藥BP010W裡的類固醇生物鹼Solasodine，利用HPLC分析顯示Solasodine出現在我們的BP010W 20%和BP010W 50%的分離物中，也經過加藥實驗證明Solasodine會抑制肺癌細胞的爬行能力，接著也利用西方墨點法，證明爬行相關的蛋白被抑制。最後利用爬行實驗證明了雌激素會增加肺癌細胞的爬行能力，我們也將Solasodine和雌激素共同治療，也發現彼此能互相抗衡爬行的能力。所以我們認為Solasodine可能可以當作新的肺癌治療候選藥物。

Lung cancer has a high mortality rate and a very low cure rate. The most important one is that the Metastasis rate is very high, and both radiotherapy and chemotherapy have many side effects. Currently, it is often used for the Target treatment of lung cancer. It produces strong resistance, so we hope to find new treatments, and many literatures show that natural medicines can be used to treat cancer, with lower toxicity and lower side effects. After drug screening, it was found that Traditional Chinese Medicine BP010W can inhibit the migration ability of lung cancer cells., thus was selected for further research. The column extraction was performed for isolation of prue compounds from BP010W using different concentrations of ethanol, 0%, 20%, 50% and 95%, and we found the concentrations of 20% and 50% have most effective in inhibiting migration of cell. We assay the bioinformatics and literature references, and It is concluded that the estrogen pathway affects the regulation of lung cancer. Therefore, we screened out the steroid alkaloid Solasodine in Chinese medicine BP010W. HPLC analysis showed that Solasodine appeared in our BP010W 20% and BP010W 50% isolates. It was also confirmed by dosing experiments that Solasodine inhibited the migration ability of lung cancer cells, and then used Western blotting to prove that the migration-related proteins were inhibited. Finally, we using the wound-Healing assay to prove that estrogen will increase the migration ability of lung cancer cells, we also treated Solasodine and estrogen together, and found that each other can compete with each other.

1. Cronin, K. A., Lake , A. J., Scott , S., et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 2018;124(13):2801-2814.
2. Yanagawa, N., Shiono, S., Abiko, M., et al. New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma. J Thorac Oncol. 2013;8(5):612-618.
3. Mollberg, N., Surati, M., Demchuk, C., et al. Mind-mapping for lung cancer: towards a personalized therapeutics approach. Advances in Therapy. 2011;28(3):173-194.
4. Murakami , S., Ito , H., Tsubokawa, N., et al. Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma. Lung Cancer. 2015;90(2):199-204.
5. Travis , W., Brambilla, E., Noguchi , M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-85.
6. Gu , J., Lu , C., Guo , J, et al. Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma. J Surg Oncol. 2013;107(5):474-80.
7. Carr , S., Akerley , W., & Cannon-Albright , L. Genetic Contribution to Nonsquamous, Non-Small Cell Lung Cancer in Nonsmokers. J Thorac Oncol., 2018;13(7):938-945.
8. Faeh, D., Kaufmann, M., Haile, S., & Bopp, M. BMI–mortality association: shape independent of smoking status but different for chronic lung disease and lung cancer. International Journal of COPD. 2018;2018(13):1851-1855.
9. Yu , D., Zheng , W., Johansson , M., et al. Overall and Central Obesity and Risk of Lung Cancer: A Pooled Analysis. J Natl Cancer Inst. 2018;110(8):831-842.
10. Lagerwaard , F., Levendag , P., Nowak , P., et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999;43(4):795-803.
11. Popper, H. Progression and metastasis of lung cancer. Cancer Metastasis Rev. 2016;35:75-91.
12. Kris , M., Natale , R., Herbst , R., et al. T. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149-58.
13. Fukuoka , M., Yano , S., Giaccone , G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21(12):2237-46.
14. Mitsudomi , T., Morita , S., Yatabe , Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121-8.
15. Dagogo-Jack, I., Brannon , A., Ferris , L., et al. Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. JCO Precis Oncol. 2018
16. Huang , C., Fong , Y., Lee , C., et al. CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochem Pharmacol. 2009;77(5):794-803.
17. Akca , H., Demiray , A., Tokgun , O, etal. Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells. Lung Cancer. 2011;73(3):302-9.
18. Geiger , B., Bershadsky , A., Pankov , R, et al. Transmembrane crosstalk between the extracellular matrix--cytoskeleton crosstalk. Nat Rev Mol Cell Biol. 2001;2(11):793-805.
19. Raines, E. The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease. Int J Exp Pathol. 2000;81(3):173-82.
20. Ryu , B., Lee , H., Kim , S., et al. PF-3758309, p21-activated kinase 4 inhibitor, suppresses migration and invasion of A549 human lung cancer cells via regulation of CREB, NF-κB, and β-catenin signaling. Mol Cell Biochem. 2014;389(1-2):69-77.
21. Legrand , C., Gilles , C., Zahm , J., et al. Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodeling. J Cell Biol. 1999;146(2):517-29.
22. Sun , S., Schiller , J.Gazdar, et al. A. Lung cancer in never smokers--a different disease. Nat Rev Cancer. 2007;7(10):778-90.
23. Patel , J., Bach, P., Kris M, et al.Lung cancer in US women: a contemporary epidemic. JAMA. 2004;291(14):1763-8.
24. Pietras , R., Márquez , D., Chen , H., et al. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids. 2005;70(5-7):372-81.
25. Bracke , M., Van Roy , F., Mareel , M, et al. The E-cadherin/catenin complex in invasion and metastasis. Curr Top Microbiol Immunol. 1996;213(Pt 1):123-61.
26. John , A., Tuszynski , G, et al. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 2001;7(1):14-23.
27. Liu, K., Zhang, J., Ren, J.-J, et al. Interference of human Na/K-ATPaseB1 subunit on proliferation. Chinese Journal of Cancer.2009;28(3):189-194.
28. Kuriyama, S., Yoshida , M., Yano , S, et al. LPP inhibits collective cell migration during lung cancer dissemination. 2016;35(8): 952-64.
29. Zhou, H., Zhang, Z., Liu , C, et al. B4GALT1 gene knockdown inhibits the hedgehog pathway and reverses multidrug resistance in the human leukemia K562/adriamycin-resistant cell line. IUBMB Life. 2012; 64(11):889-900.
30. Funato , K., Yamazumi , Y., Oda , T, et al. Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44. Exp Ther Med. 2011; 2(3):457-463.
31. Keita , M., Bachvarova , M., & Morin , C, et al. The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle. 2013; 12(6):972-86.

32. Liu, D., Hu, J., Agorreta, J, et al.. Tumor necrosis factor receptor-associated protein 1(TRAP1) regulates genes involved in cell cycle and metastases. Cancer Lett. 2010;296(2):194-205.
33. Song, L., Chang, R.,Dai, C, et al. SORBS1 suppresses tumor metastasis and improves the sensitivity of cancer to chemotherapy drug. Oncotarget,2017;8(6): 9108-9122.
34. Kawakami, K., Fujita , Y., Kato , T, et al. Integrin β4 and vinculin contained in exosomes are potential markers for progression of prostate cancer associated with taxane-resistance. Int J Oncol. 2015; 47(1): 384-90.
35. Janes, K. A. When microarrays Met epidermal‐cell migration. Molecular Systems Biology. 2008.
36. LeaoM, AlexopoulouAN, CaballeroOL, et al. Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines. Breast Cancer Res. 2010 ;12(4).
37. Ma , Z., Qiu , X., Wang , D, et al. MiR-181a-5p inhibits cell proliferation and migration by targeting Kras in non-small cell lung cancer A549 cells. Acta Biochim Biophys Sin (Shanghai). 2015;47(8).
38. Liang , S., He , L., Zhao , X, et al. MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer. PLoS One. 2011;6(4).